Etranacogene dezaparvovec

N/A

Report date: 2025/02/20 11:50:05

Base Information

Drug NameEtranacogene dezaparvovec
Drug Alias NameAAV5-FIX-PaduaEtranaDezLanacogene vosiparvovecHEMGENIXAMT-060 +[10] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV5 vector
Mechanisms of ActionBlood coagulation pathway activationCoagulation factor IX modulatorsFactor IX gene transference
TargetsCoagulation factor IX
Therapy Area/IndicationsHemophilia B
Global Approved IndicationsHemophilia B
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2022/11/22
Country/TerritoryBelgiumUnited StatesEurope +[10] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesUniqure Biopharma Bv
China Registration ClassN/A

Develop Information

Active CompaniesCsl BehringCsl Behring GmbhChiesi Farmaceutici SPA
Inactive CompaniesN/A
Active IndicationsHemophilia B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A